Thrombocytopenia

Recombinant Human Thrombopoietin Effective After Bone Marrow Transplantation

Published in Blood Weekly, April 19th, 2001

by Michael Greer, staff medical writer - Recombinant human thrombopoietin (rhTPO) can reverse the severe platelet deficiency that often follows bone marrow transplantation, researchers report.

"Thrombocytopenia following myelotoxic therapy is a common problem and, when severe (< 20,000/(mu)/l), can lead to severe morbidity and mortality," S.N. Wolff and colleagues wrote in the journal Bone Marrow Transplantation.

Wolff et al. found that rhTPO - the recombinant form of a peptide that stimulates megakaryocyte proliferation and differentiation - safely promoted fast platelet recovery after autologous bone marrow transplantation and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry